[1] YUE J, HUI Z, MA F, et al. 43P - Efficacy and safety of paclitaxel liposomes in combination with anti-HER-2 targeted drugs as first-line rescue therapy for HER-2-positive locally advanced or metastatic breast cancer: A retrospective, real-world study based on the Cancer Database of China National Cancer Center (NCC). Annals of Oncology (2024) 35 (suppl_4): S1418-S1425. 10.1016/annonc/annonc1685.
[2] MA F, YAN M, LI W, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial [J]. BMJ (Clinical research ed), 2023, 383: e076065.
[3] SWAIN S M, MILES D, KIM S B, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study [J]. The Lancet Oncology, 2020, 21(4): 519-30.